NTI-55
/ Nammi Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 09, 2021
Nammi Therapeutics Unveils Two Novel Immunotherapies at AACR Conference
(PRNewswire)
- "QXL138AM: Poster #1726 highlights preclinical validation of our first in class MIC comprised of a CD138-targeted antibody fused with Interferon alpha (IFNα) that is masked with a tumor-selectively releasable peptide....NTI-55: Poster #1581 highlights preclinical validation of NTI-55, a novel combination of validated immune modulator lipid prodrugs, including a TLR7 agonist and an A2AR inhibitor, that stimulates an immune response and blocks an important tumor-derived immune checkpoint."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1